S'abonner

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis - 13/07/12

Doi : 10.1016/j.jaad.2011.07.040 
David M. Pariser, MD a, , Craig L. Leonardi, MD b, Kenneth Gordon, MD c, Alice B. Gottlieb, MD, PhD d, Stephen Tyring, MD, PhD e, Kim A. Papp, MD f, Joanne Li, PhD g, Scott W. Baumgartner, MD g
a Eastern Virginia Medical School and Virginia Clinical Research Inc, Norfolk, Virginia 
b Saint Louis University School of Medicine, Saint Louis, Missouri 
c Evanston Northwestern Healthcare, Skokie, Illinois 
d Tufts Medical Center, Boston, Massachusetts 
e University of Texas Health Science Center at Houston, Houston, Texas 
f Probity Medical Research Inc, Waterloo, Ontario, Canada 
g Amgen Inc, Thousand Oaks, California 

Reprint requests: David M. Pariser, MD, Virginia Clinical Research Inc, 601 Medical Tower, Norfolk, VA 23507.

Abstract

Background

Multiple trials demonstrate the tolerability and safety of etanercept. However, there are limited data on etanercept tolerability in large populations of patients with psoriasis or with extended therapy.

Objectives

We sought to determine whether there is an increased safety risk associated with higher etanercept doses or with extended exposure in patients with psoriasis.

Methods

Integrated adverse event (AE) data from etanercept psoriasis trials were used to evaluate short-term (up to 12 weeks from controlled studies) and long-term (up to 144 weeks from uncontrolled extension studies) safety of etanercept (25 mg once weekly to 50 mg twice weekly). Long-term data were stratified by treatment regimens. Rates of noninfectious and infectious AE and standardized incidence ratios for malignancies were determined.

Results

In short-term analyses, rates of noninfectious and infectious AE and serious noninfectious and infectious AE were comparable between placebo and etanercept groups. In both short- and long-term analyses, there were no dose-related increases in these events. Cumulative event rates for serious infections were not significantly different across dose groups and over time. The standardized incidence ratios for malignancies excluding nonmelanoma skin cancers did not achieve statistical significance. There was no increase in overall malignancies with etanercept therapy compared with the psoriasis population. Lymphoma (n = 2 patients), demyelination (n = 2), congestive heart failure (n = 7), and opportunistic infection (n = 1) were rare.

Limitations

Study limitations include the rarity of some events and the resultant broad 95% confidence intervals.

Conclusions

In this integrated analysis, etanercept was well tolerated, and there were no signs of dose-related or cumulative toxicity over time.

Le texte complet de cet article est disponible en PDF.

Key words : clinical trials, etanercept, long-term treatment, psoriasis, safety

Abbreviations used : AE, BCC, BIW, CHF, CI, MI, MTX, NMSC, QW, SCC, SEER, SIR, TNF


Plan


 Supported by Immunex Corp, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer Inc in October 2009.
 Disclosure: Dr Pariser has been a consultant and/or advisory board member for Abbott, Galderma, and Stiefel, and he has been investigator for Abbott, Amgen, Basilea, Dow, Eli Lilly, Galderma, Johnson and Johnson Consumer Products, Leo, MELA Sciences, Novo Nordisk, Peplin, Pfizer, Photocure, Shionogi, and Stiefel. Dr Leonardi has been a consultant for Abbott, Amgen, Centocor, and Pfizer; been an investigator for Abbott, Amgen, Celgene, Centocor, Genentech, Eli Lilly, Genzyme, Pfizer, Incyte, Schering-Plough, Novartis, Novo Nordisk, Vascular Biogenics, and Wyeth (Wyeth was acquired by Pfizer in October 2009); and served as a speaker for Abbott, Amgen, and Centocor. Dr Gordon has been a consultant and/or advisory board member for Abbott, Amgen, Celgene, Centocor, Lilly, Merck, and Medicis, and he has been an investigator for Amgen, Abbott, Centocor, and Celgene. Dr Gottlieb is a consultant and/or advisory board member for Abbott, Actelion, Alnylam, Amgen, Astellas, Beiersdorf, BIND Biosciences, Bristol Myers Squibb, Canfite, Centocor, Celgene, Cytokine Pharmasciences, Dermipsor, Immune Control, Incyte, Magen Biosciences, Merck, Novo Nordisk, Ono, Pfizer, PureTech, Schering, TEVA, and UCB, and has been a recipient of research/educational grants paid to Tufts Medical Center by Abbott, Amgen, Celgene, Centocor, Immune Control, Novartis, Novo Nordisk, Pfizer, and UCB. Dr Tyring has been an investigator and speaker for Amgen. Dr Papp has been a consultant, advisory board member, and investigator for Abbott, Amgen, Celgene, Centocor, Janssen Ortho, MedImmune, Pfizer, Schering-Plough, and Wyeth (Wyeth was acquired by Pfizer in October 2009), and has served as a speaker for Amgen, Abbott, Celgene, Janssen Ortho, Pfizer, Schering-Plough, and Wyeth (Wyeth was acquired by Pfizer in October 2009). Drs Li and Baumgartner are employees and stock holders of Amgen.


© 2011  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 67 - N° 2

P. 245-256 - août 2012 Retour au numéro
Article précédent Article précédent
  • Prevalence of autosomal recessive congenital ichthyosis: A population-based study using the capture-recapture method in Spain
  • Angela Hernández-Martín, Ignacio Garcia-Doval, Beatriz Aranegui, Pablo de Unamuno, Laura Rodríguez-Pazos, Maria-Antonia González-Enseñat, Asunción Vicente, Ana Martín-Santiago, Begoña Garcia-Bravo, Marta Feito, Eulalia Baselga, Sara Círia, Raúl de Lucas, Manuel Ginarte, Rogelio González-Sarmiento, Antonio Torrelo
| Article suivant Article suivant
  • Difficulty with surgical site identification: What role does it play in dermatology?
  • Kathleen M. Rossy, Naomi Lawrence

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.